Search the Newsreel

Akari Therapeutics (AKTX) posts larger loss and flags going concern risk

Akari Therapeutics reports Q2 2026 net loss $4.8M, raises ~$8.6M, advancing AKTX-101 toward mid-2027 Phase 1

Akari Therapeutics reported a net loss of $4.8 million for Q2 2026 and held $7.7 million in cash. The company raised approximately $8.6 million in gross proceeds through a private placement and warrant exercises. Akari is advancing its lead ADC candidate, AKTX-101, towards a …

Akari Therapeutics (AKTX) sees Bank of Montreal group report 5.71% ownership

Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. have reported beneficial ownership of 8,000,000,000 Ordinary Shares of Akari Therapeutics (AKTX), representing 5.71% of the outstanding class as of June 30, 2026. The entities hold these shares as prime broker …

White Lion Capital reports 5% Akari Therapeutics (AKTX) stake via equity line

White Lion Capital LLC has reported a 5% beneficial ownership stake in Akari Therapeutics Plc (AKTX) through an equity line Common Stock Purchase Agreement. This ownership amounts to 7,001,638,477 ordinary shares, represented by American Depositary Shares, out of 140,032,769,533 ordinary shares outstanding as of …

Akari Therapeutics PLC (AKTX) Stock News Today

Akari Therapeutics PLC (AKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Interim CFO of Akari Therapeutics Plc (AKTX) awarded 1,130 ADS RSUs

Akari Therapeutics Plc's interim CFO, Farag Kameel D., was awarded 1,130 American Depositary Shares (ADSs) representing restricted stock units (RSUs) on July 16, 2026, at a reported price of $11.50 per share. These RSUs will fully vest on August 16, 2026, with each RSU …

Akari Therapeutics, Plc (AKTX) stock price, news, quote and history

This article provides a comprehensive overview of Akari Therapeutics, Plc (AKTX) stock, including its real-time price, historical data, and key financial metrics. It highlights the company's focus on developing antibody-drug conjugates (ADCs) for cancer treatment, with lead products like AKTX-101 and AKTX-102. The report …

Akari Therapeutics CEO highlights WhiteHawk dual-payload ADC strategy

Akari Therapeutics announced a research collaboration with WhiteHawk Therapeutics to evaluate a dual-payload Antibody Drug Conjugate (ADC) strategy, combining Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor. CEO Abizer Gaslightwala emphasized this partnership could accelerate innovation and broaden therapeutic activity in oncology. Akari also …

Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation

Akari Therapeutics has released a new CEO Corner segment featuring CEO Abizer Gaslightwala, discussing the strategic research collaboration with WhiteHawk Therapeutics. This collaboration aims to combine Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor ADC platform to explore a novel dual-payload strategy, which Akari …

Price to earnings forward of Akari Therapeutics Plc – NASDAQ:AKTX

The article focuses on the "Price to earnings forward" metric for Akari Therapeutics Plc (NASDAQ: AKTX). It presents a financial data point for the company, indicating the period and value of this specific financial ratio. The content primarily appears to be a data display …

Akari Therapeutics Plc Revenue Breakdown – NASDAQ:AKTX

This article provides a brief overview of Akari Therapeutics Plc (NASDAQ: AKTX) financials, specifically focusing on its revenue breakdown. It indicates that further detailed financial information, including segments and regional performance, is available through TradingView and its data partners like ICE Data Services and …

Akari Therapeutics PLC (AKTX) Income Statement

This article provides the income statement for Akari Therapeutics PLC (AKTX), detailing quarterly and annual financial performance metrics such as total revenue, operating expenses, R&D expenses, operating profit, net income, and earnings per share. It allows users to gain insights into the company's operational …

Akari Therapeutics PLC (AKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Akari Therapeutics PLC (AKTX) dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and lists several stock mergers, including a 40-to-1 merger in March 2026 and multiple …

Akari Therapeutics PLC (AKTX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Akari Therapeutics PLC (AKTX), focusing on its P/E, P/B, and Fair Value. It notes that relevant data for P/E, P/B, and P/CF ratios have not yet been disclosed by the company. The stock is currently trading at …

Akari Therapeutics PLC (AKTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Akari Therapeutics PLC (AKTX), listing both major individual and institutional holders. It provides a breakdown of shareholder types, including individual investors, hedge funds, and investment advisors, along with a historical overview of institutional shareholding changes over several …

Akari Therapeutics PLC (AKTX) Institutional Confidence

This article from TradingKey provides an overview of Akari Therapeutics PLC (AKTX), focusing on its institutional confidence and shareholder activity. It lists key institutional shareholders and their holdings, offering a snapshot of who is investing in the company. The data includes the number of …

Akari Therapeutics PLC (AKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Akari Therapeutics PLC (AKTX) stock, covering support, resistance, technical indicators, and moving averages. It details various indicators like MACD, RSI, and KDJ, with their values and directional signals, alongside moving average data. The analysis concludes with a …

Akari Therapeutics PLC (AKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Akari Therapeutics PLC (AKTX), focusing on volatility, financial risk, and investment risk metrics. It includes data points such as Beta vs S&P 500 index, VaR, maximum drawdown, Sharpe Ratio, and various volatility measures over different timeframes, …

AKTX|Akari Therapeutics PLC|Price:8.700|Chg%:-0.600

This article provides a detailed financial overview of Akari Therapeutics PLC (AKTX), including its current stock price, market capitalization, performance metrics, and analyst ratings. It highlights the company's focus on developing precision bifunctional antibody drug conjugates (ADCs) for cancer treatment, mentioning its lead candidate …

Price to sales forward of Akari Therapeutics Plc – NASDAQ:AKTX

This article provides a brief financial update on Akari Therapeutics Plc (NASDAQ: AKTX), specifically focusing on its price-to-sales forward metric. The content indicates that while the market is closed, the company's financial data is available through TradingView, but the specific value for the price-to-sales …

Akari Therapeutics Plc Sponsored ADR Revenue Breakdown – LS:A4270Y

This page provides financial information for Akari Therapeutics Plc Sponsored ADR (LS:A4270Y) on TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment breakdown options. The content primarily highlights navigation and data sourcing details rather than specific financial …

Akari Therapeutics CEO Explains Why Growing Industry Demand

Akari Therapeutics' CEO, Abizer Gaslightwala, highlighted the growing industry demand for next-generation ADC payloads during a Virtual Investor interview, focusing on the company's strategic collaboration with Whitehawk Therapeutics. This partnership aims to evaluate Akari's proprietary PH1 spliceosome modulating payload technology alongside Whitehawk's TOP1i ADC …

Enterprise value to revenue forward of Akari Therapeutics Plc – NASDAQ:AKTX

This article provides a brief title indicating a focus on the enterprise value to revenue forward for Akari Therapeutics Plc (NASDAQ: AKTX). The content appears to be a stub or an incomplete data entry, likely from a financial platform, showing no actual data or …

Price to earnings forward of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1

The article displays the "Price to earnings forward" metric for Akari Therapeutics Plc Sponsored ADR (CLA1) on the Tradegate Exchange. It indicates no trades and provides an overview of financial data and community features. The page primarily serves as a financial data display for …

Akari Therapeutics (AKTX) Registration filing Summary

Akari Therapeutics' recent registration filing highlights its focus on developing next-generation antibody-drug conjugates (ADCs) for solid tumors, with lead candidate AKTX-101 in preclinical stages aiming for a Phase 1 trial by mid-2027. The company's financial position as of December 31, 2025, shows $5.2 million …

Form 4 Akari Therapeutics PLC For: 17 July By Investing.com

This article from Investing.com reports the filing of a Form 4 for Akari Therapeutics PLC. The filing is related to activity on July 17, as indicated by the title. The article provides the company's stock symbol AKTX and its current price performance.

Akari Therapeutics (AKTX) director exercises pre-funded warrants for 22,474 ADSs

Akari Therapeutics director Samir Rashmikant Patel, through PranaBio Investments LLC, exercised pre-funded warrants on July 7, 2026, to acquire 22,474 American Depositary Shares (ADSs). These exercises involved different price points ($0.0004 and $8.00 per ADS) and were not part of a Rule 10b5-1 trading …

Akari Therapeutics (AKTX) Q1 2026 earnings summary

Akari Therapeutics (AKTX) reported a Q1 2026 net loss of $14.5 million, significantly higher than Q1 2025 due to non-cash impairment charges. The company is focused on advancing its lead ADC program, AKTX-101, towards a Phase 1 trial by mid-2027 but faces substantial doubt …

Akari Therapeutics Q1 2026 Earnings: EPS Misses Estimates, Stock Surges Over 40% - Profit Cycle Analysis

Akari Therapeutics Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 5.7% on Pipeline Hope - Surprise Factor Analysis

Akari Therapeutics Q1 2026 Earnings: EPS Miss Amid No Revenue, Stock Surges 51.5% - Post-Earnings Drift

VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session